Tersolisib

Tersolisib

Tersolisib

Tersolisib
Clinical data
Other namesLY4064809
Identifiers
  • 1-(2-aminopyrimidin-5-yl)-3-[(1R)-1-(5,7-difluoro-3-methyl-1-benzofuran-2-yl)-2,2,2-trifluoroethyl]urea
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
Chemical and physical data
FormulaC16H12F5N5O2
Molar mass401.297 g·mol−1
3D model (JSmol)
  • CC1=C(OC2=C1C=C(C=C2F)F)[C@H](C(F)(F)F)NC(=O)NC3=CN=C(N=C3)N
  • InChI=InChI=1S/C16H12F5N5O2/c1-6-9-2-7(17)3-10(18)12(9)28-11(6)13(16(19,20)21)26-15(27)25-8-4-23-14(22)24-5-8/h2-5,13H,1H3,(H2,22,23,24)(H2,25,26,27)/t13-/m1/s1
  • Key:LGPNQALKGDDVBD-CYBMUJFWSA-N

Tersolisib is an investigational new drug that is being evaluated by Eli Lilly and Company for the treatment of solid tumors. It is a PI3Kα inhibitor.[1][2]

References

  1. ^ "Tersolisib - Eli Lilly and Company". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Schmitz AE, Udgata S, Johnson KA, Deming DA (May 2025). "The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies". Biomedicines. 13 (6): 1319. doi:10.3390/biomedicines13061319. PMC 12189650. PMID 40564038.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.